Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trisha M Wise-Draper

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Cancer Letters|November 3, 2024
Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinomaJulianna Korns, Christina A Wicker, Maria Lehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck CancerJulianna Korns, Maria A Lehn, Shreya Shyamsunder, et al.
Cancers of the Head & Neck|September 18, 2020
Determining the molecular landscape and impact on prognosis in HPV-associated head and neck cancerSuchin Khanna, Sarah Palackdharry, Logan Roof, et al.
Frontiers in Pharmacology|September 13, 2021
Immune Checkpoint Inhibitors Regulate K<sup>+</sup> Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer PatientsVaibhavkumar S Gawali, Ameet A Chimote, Hannah S Newton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2023
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical TrialShuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, et al.
Scientific Reports|October 17, 2025
KCa3.1 channels regulate the tumor infiltration of functionally competent NK cells in head and neck cancerAbdulaziz O Alshwimi, Ameet A Chimote, Marat V Khodoun, et al.
The Laryngoscope|February 20, 2021
Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint InhibitorsJennifer L Leddon, Martina Chirra, Andrew J Frankart, et al.
Cancers|December 24, 2021
Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival OutcomesHira Shaikh, Julie E McGrath, Brittany Hughes, et al.
JAMA Otolaryngology-- Head & Neck Surgery|August 25, 2022
Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive PatientsAlice L Tang, Thomas O'Neil, Sean McDermott, et al.
Oral Oncology|September 19, 2025
Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencingJimmy A Vareta, Xiang Zhang, Damaris Kuhnell, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Cancer Letters|November 3, 2024
Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinomaJulianna Korns, Christina A Wicker, Maria Lehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck CancerJulianna Korns, Maria A Lehn, Shreya Shyamsunder, et al.
Cancers of the Head & Neck|September 18, 2020
Determining the molecular landscape and impact on prognosis in HPV-associated head and neck cancerSuchin Khanna, Sarah Palackdharry, Logan Roof, et al.
Frontiers in Pharmacology|September 13, 2021
Immune Checkpoint Inhibitors Regulate K<sup>+</sup> Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer PatientsVaibhavkumar S Gawali, Ameet A Chimote, Hannah S Newton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2023
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical TrialShuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, et al.
Scientific Reports|October 17, 2025
KCa3.1 channels regulate the tumor infiltration of functionally competent NK cells in head and neck cancerAbdulaziz O Alshwimi, Ameet A Chimote, Marat V Khodoun, et al.
The Laryngoscope|February 20, 2021
Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint InhibitorsJennifer L Leddon, Martina Chirra, Andrew J Frankart, et al.
Cancers|December 24, 2021
Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival OutcomesHira Shaikh, Julie E McGrath, Brittany Hughes, et al.
JAMA Otolaryngology-- Head & Neck Surgery|August 25, 2022
Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive PatientsAlice L Tang, Thomas O'Neil, Sean McDermott, et al.
Oral Oncology|September 19, 2025
Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencingJimmy A Vareta, Xiang Zhang, Damaris Kuhnell, et al.
Pageof 8